| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T29143 | ||||
| Target Name | Interleukin-13 | ||||
| Target Type | Clinical Trial |
||||
| Action against Disease Model | Tralokinumab | BALB/c mice were treated on days 1 and 3 with CAT-354 (intraperitoneal injection), and h uMan IL-13 was injected intratracheally on days 2 and 4. AHR to methacholine, airway eosinophilia in bronchoalveolar lavage fluid, histologic analysis of goblet cell metaplasia and oesophageal eosinophilia were evaluated. H uMan IL-13 induced airway eosinophilia and goblet cell metaplasia in mice in a dose-dependent manner. Moreover, intratracheal dosing with 25 microg of h uMan IL-13 was sufficient to induce AHR, goblet cell metaplasia and oesophageal eosinophilia. Pretreatment withCAT-354 significantly reduced AHR, airway eosinophilia and oesophageal eosinophilia. These results demonstrate that anti-h uMan IL-13 (CAT-354) is a potential therapeutic treatment for allergic airway and oesophageal diseases. | [552543] | Drug Info | |
| The Effect of Target Knockout, Knockdown or Genetic Variations | Gene deletion resulted in Remodelling response decrease compared to wild type | [552543] | |||
| References | |||||
| Ref 552543 | Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005 Aug;35(8):1096-103. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.